In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing

Clinical Cancer Research

Volumn 22, Issue 17, 2016, Pages 4417-4427

  Lehmann, Steffi ^a,b   Perera, Ramanil ^a,b   Grimm, Hans Peter ^c   Sam, Johannes ^a   Colombetti, Sara ^a   Fauti, Tanja ^a   Fahrni, Linda ^a   Schaller, Teilo ^a   Freimoser Grundschober, Anne ^d   Zielonka, Jörg ^d   Stoma, Szymon ^e   Rudin, Markus ^b   Klein, Christian ^a   Umana, Pablo ^a   Gerdes, Christian ^a   Bacac, Marina ^a  

^a Roche Pharmaceutical Research and Early Development   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Roche Pharmaceutical Research and Early Development   (Switzerland)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CEA TCB ANTIBODY; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CYTOLYSIS; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; EXTRAVASCULAR SPACE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPHOTON MICROSCOPE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TIME LAPSE IMAGING; TUMOR CELL; ANIMAL; ANTIBODY SPECIFICITY; CELL COMMUNICATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULAR IMAGING; NEOPLASM; PROCEDURES; TIME FACTOR; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS; CARCINOEMBRYONIC ANTIGEN; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84979262907     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2622     Document Type: Article

References (27)

1. Baeuerle P, Zugmaier G, Rüttinger D. Bispecific T cell engager for cancer therapy. In: Kontermann RE, editor. Bispecific antibodies: Heidelberg: Springer; 2011.p. 273-87.
2. Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res 2014;74:7168-74.
3. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2015;93:290-6.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25: 267-96.
5. Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther 2015;15:895-908.
6. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136:334-42.
7. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17:385-92.
8. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A novel carcinoembryonic antigen T cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res 2016 Feb 9. [Epub ahead of print].
9. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
10. Bullen A. Microscopic imaging techniques for drug discovery. Nat Rev Drug Discov 2008;7:54-67.
11. Ottobrini L, Martelli C, Trabattoni DL, Clerici M, Lucignani G. In vivo imaging of immune cell trafficking in cancer. Eur J Nucl Med Mol Imaging 2011;38:949-68.
12. Koehl GE, Gaumann A, Geissler EK. Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis 2009;26:329-44.
13. Rutzky LP, Tomita JT, Calenoff MA, Kahan BD. Human colon adenocarcinoma cells. III. In vitro organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture. J Natl Cancer Inst 1979;63: 893-902.
14. Dobosz M, Strobel S, Stubenrauch KG, Osl F, Scheuer W. Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice. J Biomed Opt 2014;19:16022.
15. Hillman EM, Amoozegar CB, Wang T, McCaslin AF, Bouchard MB, Mansfield J, et al. In vivo optical imaging and dynamic contrast methods for biomedical research. Philos Trans A Math Phys Eng Sci 2011;369:4620-43.
16. Hoppin J, Orcutt KD, Hesterman JY, Silva MD, Cheng D, Lackas C, et al. Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther 2011;337:350-8.
17. Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B 2010;98:77-94.
18. Conway JRW, Carragher NO, Timpson P. Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nat Rev Cancer 2014;14:314-28.
19. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397-402.
20. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-53.
21. Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 2006;203:2749-61.
22. CaramalhoI, Faroudi M, Padovan E, Müller S, Valitutti S. Visualizing CTL/ melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation. J Cell Mol Med 2009;13:3834-46.
23. Gadhamsetty S, Maree AF, Beltman JB, de Boer RJ. A general functional response of cytotoxic T lymphocyte-mediated killing of target cells. Biophys J 2014;106:1780-91.
24. Perelson AS, Macken CA, Grimm EA, Roos LS, Bonavida B. Mechanism of cell- mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol 1984;132:2190-8.
25. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104.
26. Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/ MHC-tumor peptide interactions. J Exp Med 1996;183:2403-7.
27. McMahan RH, Slansky JE. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol 2007;17:317-29.